Shares of Dova Pharmaceuticals (NASDAQ:DOVA) have earned an average rating of “Hold” from the six brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $32.25.
Several equities research analysts have recently issued reports on the company. BidaskClub lowered Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 29th. Evercore ISI assumed coverage on Dova Pharmaceuticals in a research note on Friday, March 23rd. They issued a “line” rating and a $29.00 price objective on the stock.
Several hedge funds have recently modified their holdings of the stock. Pier Capital LLC raised its stake in shares of Dova Pharmaceuticals by 37.2% in the 4th quarter. Pier Capital LLC now owns 160,123 shares of the company’s stock valued at $4,612,000 after acquiring an additional 43,408 shares in the last quarter. Nexthera Capital LP raised its stake in shares of Dova Pharmaceuticals by 3.4% in the 4th quarter. Nexthera Capital LP now owns 453,032 shares of the company’s stock valued at $13,047,000 after acquiring an additional 14,913 shares in the last quarter. Perceptive Advisors LLC raised its stake in shares of Dova Pharmaceuticals by 3.1% in the 4th quarter. Perceptive Advisors LLC now owns 1,809,015 shares of the company’s stock valued at $52,099,000 after acquiring an additional 55,000 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Dova Pharmaceuticals in the 4th quarter valued at approximately $461,000. Finally, Deutsche Bank AG raised its stake in shares of Dova Pharmaceuticals by 139.2% in the 4th quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock valued at $337,000 after acquiring an additional 6,836 shares in the last quarter. 26.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of Dova Pharmaceuticals stock traded up $0.38 during trading on Tuesday, hitting $25.33. 87,230 shares of the stock traded hands, compared to its average volume of 139,536. The firm has a market cap of $713.09 and a price-to-earnings ratio of -18.09. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $37.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Thursday, February 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.36). During the same period last year, the business earned ($0.44) EPS. equities research analysts predict that Dova Pharmaceuticals will post -1.45 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Dova Pharmaceuticals (DOVA) Receives Consensus Rating of “Hold” from Brokerages” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/22/dova-pharmaceuticals-dova-receives-consensus-rating-of-hold-from-brokerages.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.